The Quiet Squeeze in the Money Markets

Dear Fellow Skeptic,

There's a simple, and maybe inevitable, way to make big money - at the expense of the Chinese government.

In 2018, a small American biotech firm stunned the world when they showed they could "rewrite humans" to eliminate risk of disease.

That's because this radical breakthrough will not just change how we treat diseases -

It will determine which country is going to lead the future of medicine for the next 50 years - the United States or China.

The stakes couldn't be higher -

National Defense Magazine says the breakthrough has "China is investing billions to make itself a world leader in this."

The MIT Technology Review says the breakthrough has "world-shaping potential."

The U.S. Director of National Security says the breakthrough has "far-reaching economic and national security implications."

That's the real reason President Trump signed "Executive Order 13771" just ten days after taking office. For us to beat China, he had to reduce regulations at the FDA first.

Find out more here >>>

The commercial value of the patent is astronomical.

Investor's Business Daily estimates it's worth $75 billion. That means China, and the rest of the world, has to pay a license fee to use this new breakthrough.

And a tiny American company owns the patent on this historic treatment.

Its current market capitalization is just $1 billion. But analysts Keith Speight thinks it will be worth twice what Facebook is worth or $1 Trillion.

That would be enough to turn every $1,000 into $1,000,000 (or more) >>>

Sincerely,

Josh Kaplan
Editor,
Behind the Markets

---

The above is a paid advertisement. StockEarnings.com is not affiliated with nor does it endorse any trading system, newsletter or other similar service. StockEarnings.com does not assure or verify any performance claims made by such systems, newsletters or services. Trading involves a significant and substantial risk of loss and may not be suitable for everyone. You should only trade with money you can afford to lose. There is no assurance that you will gain from your trading activity and it is possible that you may lose all of, or if trading on margin more than, your investment. Some of the results shown may be based on simulated performance. SIMULATED OR HYPOTHETICAL PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE THE RESULTS SHOWN IN AN ACTUAL PERFORMANCE RECORD, SUCH RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, BECAUSE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MY HAVE UNDER OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED OR HYPOTHETICAL PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE GAINS OR LOSSES SIMILAR TO THOSE SHOWN.

Past performance is not necessarily indicative of future performance. This brief statement cannot disclose all the risks and other significant aspects of trading. You should carefully study trading and consider whether such activity is suitable for you in light of your circumstances and financial resources before you trade.
This message is considered by regulation to be a commercial and advertising message. This is a permission-based message. You are receiving this email either because you opted-in to this subscription or because you have a prior existing relationship with StockEarnings.com or one of its subsidiaries, and previously provided your email address to us. This email fully complies with all laws and regulations. If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking on the unsubscribe or profile link and you will no longer receive this email. We will immediately redress any complaints you may have. If you have any questions, please send an email with your questions to info@stocksearning.com.

If you would no longer like to receive StockEarnings partners and advertisers emails, you can click here to unsubscribe.